SU 6668 Chemical Properties

storage temp. 

+2C to +8C

solubility 

DMSO : 50 mg/mL (161.11 mM; Need ultrasonic)

form 

Dark yellow solid

SU 6668 Usage And Synthesis

Uses

PDGFR Tyrosine Kinase Inhibitor VI, SU6668 is a potent ATP-competitive inhibitor against tyrosine kinases.

General Description

A cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC₅₀ = 0.01, 0.1, 3.9, and 3.8 μM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development in vivo. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC₅₀ = 0.85, 0.047, 1.4, and 1.8 μM, respectively), as well as non-receptor TKs Lyn and Yes (IC₅₀ = 4.3 and 5.8 μM, respectively).

SU 6668(210644-62-5)Related Product Information

• 3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-pyrrolidine-2,5-dione
• INCB39110
• X-376
• Filgotinib
• Decernotinib
• Masitinib
• Lestaurtinib
• CAL-101
• PLX3397 (Pexidartinib)
• CO-1686
• Momelotinib
• 790299-79-5
• AZD-6244
• ARRY-334543
• Dovitinib
• Volitinib